Volume 12, Number 3—March 2006
Letter
"Mycobacterium tilburgii" Infections
Dirk Wagner*
, Margreet C. Vos†‡, Anton G.M. Buiting‡, Annerose Serr*, Anneke M.C. Bergmans§, Winfried V. Kern*, and Leo M. Schouls¶
, Margreet C. Vos†‡, Anton G.M. Buiting‡, Annerose Serr*, Anneke M.C. Bergmans§, Winfried V. Kern*, and Leo M. Schouls¶Table
Characteristics of patients with confirmed "Mycobacterium tilburgii" disease*
| Sex (age, y) | Immuno-suppression | CD4 count (cell/μL) | Disease manifestation | Treatment (duration, mo) | Diagnosed in | Reference |
|---|---|---|---|---|---|---|
| F (45) | No | Normal | Bladder, intestinal lymphnodes, stomach, ileum, colon | Pyrazinamide, isoniazid, rifampin (5); ethambutol, ciprofloxacin, clarithromycin, rifampin (11); surgical resection | The Netherlands | This study |
| M (34) | AIDS | 37 | Esophagus, duodenum | Ethambutol, clarithromycin, rifabutin (5) | Germany | This study |
| M (35) | AIDS | 20 | Duodenum, abdominal lymph nodes | Ethambutol, clarithromycin, rifabutin (12†) | Germany | (9) |
| M (41) | AIDS | 17 | Pulmonary nodules | Surgical resection; ethambutol, ciprofloxacin, clarithromycin (6); ethambutol, clarithromycin (12‡) | Germany | (10) |
